CN-122012356-A - Lactobacillus amylovorus and probiotic bacterial agent and application thereof

Abstract

The invention discloses a lactobacillus amylovorus and probiotic bacteria agent and application thereof. The Lactobacillus amylovorus (Lactobacillus amylovorus) is named as Lactobacillus amylovorus YI39, the preservation number of the Lactobacillus amylovorus in China center for type culture collection is CCTCC NO: M2026104, and the nucleotide sequence of the 16SrDNA is SEQ ID NO.1. The Lactobacillus amylovorus YI39 provided by the invention is separated from the ileum content of 28-day-old healthy rapid yellow-feather broilers, has strong probiotics, has better capability of inhibiting the growth of salmonella pullorum, pathogenic escherichia coli of birds, clostridium perfringens type A and staphylococcus aureus, and can effectively regulate and control the body of the broilers so as to prevent necrotic enteritis of the chickens caused by clostridium perfringens infection.

Inventors

• HE XI
• SONG ZEHE
• HUANG YUXIN

Assignees

• 湖南农业大学

Dates

Publication Date

20260512

Application Date

20260416

Claims (8)

1. 1. The lactobacillus amylovorus for preventing necrotic enteritis of chickens caused by clostridium perfringens infection is characterized in that the lactobacillus amylovorus (Lactobacillus amylovorus) is named as lactobacillus amylovorus YI39, the preservation number of the lactobacillus amylovorus in China center for type culture collection is CCTCC NO: M2026104, the nucleotide sequence of 16SrDNA of the lactobacillus amylovorus is SEQ ID NO.1, and the lactobacillus amylovorus is derived from broilers.
2. 2. A probiotic bacterial agent, characterized in that the probiotic bacterial agent comprises the lactobacillus amylovorus according to claim 1.
3. 3. The probiotic bacteria agent according to claim 2, characterized in that it further comprises an auxiliary material, which is maltodextrin.
4. 4. A probiotic bacterial agent according to claim 2 or 3, characterized in that the probiotic bacterial agent is in the form of a liquid, powder or granule.
5. 5. The probiotic bacterial agent according to claim 4, characterized in that the formulation of the probiotic bacterial agent is a freeze-dried powder.
6. 6. Use of the lactobacillus amylovorus of claim 1 or the probiotic bacterial agent of any of claims 2 to 5 in the preparation of a feed or medicament for preventing and/or treating necrotic enteritis in chickens caused by clostridium perfringens infection in broilers.
7. 7. The use according to claim 6, wherein the feed or medicament has at least one of the following functions: (1) The average daily gain of broiler chickens after clostridium perfringens detoxication is improved; (2) Reducing jejunum lesion score caused by toxin attack and increasing the ratio of the villus height to the crypt depth; (3) Simultaneously reducing the contents of diamine oxidase and interleukin-1 beta in serum, and up-regulating the mRNA expression level of the tight junction protein Claudin-1 in jejunum tissues; (4) Antibacterial function.
8. 8. The use according to claim 7, wherein the bacteriostatic action comprises an inhibitory action on at least one of salmonella pullorum, avian pathogenic escherichia coli, clostridium perfringens type a, staphylococcus aureus.

Description

Lactobacillus amylovorus and probiotic bacterial agent and application thereof Technical Field The invention relates to the technical field of microorganisms, in particular to a lactobacillus amylovorus and probiotic bacteria agent and application thereof. Background Poultry farming is an important component of our livestock industry. Among them, necrotic enteritis (Necrotic Enteritis, NE) in chickens caused by clostridium perfringens (Clostridium perfringens) is a common acute infectious disease, which causes a huge economic loss to the poultry industry worldwide. The disease mainly invades the small intestine of the chicken, causes necrosis of intestinal mucosa and seriously affects the growth performance and health of the chicken. Antibiotic addition to diets has long been a major means of preventing and controlling necrotic enteritis in chickens. However, with the worldwide limitation and disability of feed antibiotic growth promoters, the incidence of necrotic enteritis in chickens has risen, and its control faces new challenges. Thus, the development of safe, effective antibiotic alternatives, such as probiotics, has become a hotspot in current research. Probiotics, particularly lactobacillus, are considered as powerful candidates for preventing and controlling intestinal diseases due to their ability to regulate intestinal flora balance, enhance intestinal barrier function, regulate immune response, etc. Some lactobacillus strains have been studied to alleviate the damage of necrotic enteritis to the intestinal tract by competitive exclusion of pathogenic bacteria, production of antibacterial substances, regulation of inflammatory factor expression, and the like. Such as CN117448213A provides a Lactobacillus plantarum inhibiting Clostridium perfringens and its progeny and uses. The Lactobacillus plantarum is named Lactobacillus plantarum (Lactobacillus plantarum) BLCC2-0072, and the strain is preserved in China center for type culture Collection (China center for type culture collection) at the year of 2023, and the preservation number is CCTCC NO: M2023842. The bacterium has good antibacterial activity, and particularly has excellent inhibition effect on various clostridium perfringens. Although the probiotic efficacy of lactobacillus has been widely accepted, there are significant differences in the probiotic properties of different species and different strains. Lactobacillus amylovorus (Lactobacillus amylovorus) is used as a potential probiotic, and the application of the lactobacillus amylovorus in the aspect of preventing necrotic enteritis of chickens has not been reported. Based on the above, the invention aims to provide a novel lactobacillus amylovorus strain which can effectively inhibit clostridium perfringens and enhance the anti-infection capability of broiler chickens. Disclosure of Invention Aiming at the problems existing in the prior art, the invention provides the lactobacillus amylovorus and probiotic bacterial agent and the application thereof, has strong probiotic characteristics and good antibacterial activity, and can effectively regulate and control the body of broiler chickens so as to prevent necrotic enteritis of chickens caused by clostridium perfringens infection. In order to solve the technical problems, the invention adopts the following technical scheme: In a first aspect, the invention provides a lactobacillus amylovorus (Lactobacillus amylovorus) named as lactobacillus amylovorus YI39, which has a preservation number of CCTCC NO: M2026104 in China center for type culture collection, and a nucleotide sequence of 16SrDNA of the lactobacillus amylovorus is SEQ ID NO.1. In a second aspect, the invention provides a probiotic bacterial agent, which is characterized in that the probiotic bacterial agent comprises lactobacillus amylovorus as described above. Preferably, the viable bacteria concentration of the lactobacillus amylovorus in the probiotic bacterial agent is 3×10 8 CFU/kg~3×108 CFU/kg. Further, the probiotic bacterial agent also comprises auxiliary materials, and the auxiliary materials are maltodextrin. Further, the formulation of the probiotic bacteria agent is liquid, powder or granule. Furthermore, the probiotic bacteria agent is in the form of freeze-dried powder. In a third aspect, the invention also provides the use of a lactobacillus amylovorus or a probiotic bacterial agent as described above in the manufacture of a feed or medicament for the prevention and/or treatment of necrotic enteritis in poultry. Further, the poultry is broiler chicken. Further, necrotic enteritis is necrotic enteritis in chickens caused by clostridium perfringens infection. Further, the feed or medicament has at least one of the following functions: (1) The average daily gain of broiler chickens after clostridium perfringens detoxication is improved; (2) Reducing jejunum lesion score caused by toxin attack, and increasing the ratio of the villus height to the crypt depth (villus